Austar Lifesciences Limited (HKG:6118)

Market Cap	363.93M -55.6%
Revenue (ttm)	1.70B +2.0%
Net Income	37.62M +110.2%
EPS	0.07 +110.2%
Shares Out	512.58M
PE Ratio	9.67
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,000
Open	0.6800
Previous Close	0.7200
Day's Range	0.6700 - 0.7100
52-Week Range	0.6500 - 1.8200
Beta	0.89
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Austar Lifesciences

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC) segments. The company also offers clean utility equipment and chemical pharmaceutical preparation systems; bioprocess equipment and systems; clean room, automation control, ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1991
• Employees: 1,468
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6118

Financial Performance

In 2025, Austar Lifesciences's revenue was 1.53 billion, an increase of 2.02% compared to the previous year's 1.50 billion. Earnings were 33.81 million, an increase of 110.24%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error